Sling Therapeutics Appoints Ken Lock as Chief Commercial Officer
BUSINESS WIRE)-- Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid eye disease (TED), today announced the appointment of Ken Lock as Chief Commercial Officer.
Linsitinib has the potential to be a transformative oral small molecule therapy for TED patients, offering a compelling and convenient alternative to currently available treatments.
'We are delighted to welcome Ken as Sling's Chief Commercial Officer. He brings deep expertise across marketing, sales and market access in competitive markets along with a proven track record building and leading high-performing commercial organizations, which will be instrumental as we advance linsitinib to a confirmatory Phase 3 study in patients with thyroid eye disease,' said Ryan Zeidan, Ph.D., President and Chief Executive Officer of Sling Therapeutics. 'Ken shares our deep commitment to improving the lives of patients and their families, and we look forward to working alongside him to help deliver linsitinib to the people who need it most.'
'Joining Sling Therapeutics at this pivotal stage in the development of linsitinib is an exciting opportunity," shared Lock, who brings extensive U.S. and global commercial leadership experience to his role. 'Linsitinib has the potential to be a transformative oral small molecule therapy for TED patients, offering a compelling and convenient alternative to currently available treatments. I am excited to join this highly accomplished team as we work to address the significant unmet needs of TED patients.'
Most recently, Lock served as Chief Commercial Officer at ACELYRIN, where he led the commercial, medical affairs, and alliance management functions in the TED market. Lock also served as Chief Commercial Officer at Arcutis Biotherapeutics, where he built and led a team of over 130 people and was responsible for the launch and brand development of ZORYVE®. Prior to that, he held sales and marketing roles of increasing responsibility at Gilead Sciences, Amgen, and Wyeth (now Pfizer). Lock holds an M.B.A. from the Cornell Johnson Graduate School of Management and a dual B.S. and B.A. in Biochemistry/Cell Biology and Psychology from the University of California, San Diego.
About Thyroid Eye Disease (TED)
Thyroid Eye Disease (TED) is a serious, progressive, and vision-threatening rare autoimmune disease that affects approximately 70,000 people in the U.S. and has a similar prevalence in the EU. TED often occurs in people living with Graves' disease and hyperthyroidism and is caused by dysfunction in the IGF-1R signaling pathway, which results in fibrous tissue growth behind the eyes. This leads to several negative symptoms that may have long-term, irreversible damage as the tissue growth pushes the eyes forward or causes the eyes and eyelids to become red and swollen. As the disease progresses, it can lead to pain, eye bulging (proptosis), and double vision (diplopia), thus dramatically impacting a patient's quality of life. TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease. The current standard of care typically involves either invasive orbital surgery or a lengthy series of infusions with potential adverse events like loss of hearing, hyperglycemia, or menstrual cycle changes.
About Sling Therapeutics
Sling Therapeutics is an innovative biopharmaceutical company whose lead product candidate, linsitinib, has the potential to be the first oral IGF-1R inhibitor to treat thyroid eye disease (TED). Linsitinib is in late-stage clinical development for TED, which is an autoimmune disease with a significant unmet need, as current treatment options are limited to invasive orbital surgery or a lengthy series of infusions. Sling aims to bring a convenient oral therapy to improve patients' quality of life and reduce physician and healthcare system burden. For more information, visit www.slingtx.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
How Local Economic Development Act funds help New Mexico businesses grow
NEW MEXICO (KRQE) – For years, state and city grant funding has been used to grow businesses in New Mexico with the goal of keeping jobs here and boosting the economy. One local business who has expanded over the years said it's all thanks to that local funding. Vitality Works, located in Albuquerque, makes dietary and herbal supplements. 'We are the guys that really make the stuff for over 600 brands in the United States. Our name is on nothing, but we make other people's goods and fully package turnkey operations,' said Vitality Works CEO/Founder Mitch Coven. Coven said since he started his company in the 1980's, it's far surpassed his goals. He said the growth wouldn't have been possible without money from grants and tax credits. 'Everything that the city, county, state has made available to us has helped foster our growth even faster,' added Coven. One of the grants he's received is through the Local Economic Development Act, or LEDA which was signed into New Mexico law in the early 90's to incentivize and support growing businesses. 'We want the public sector to be an enabling partner that allows those entrepreneurs and those companies to be successful,' said Director of Economic Development for the City of Albuquerque Max Gruner. Vitality Works is just one company that's benefited from LEDA in the metro. In just the past eight years, the city of Albuquerque has committed more than $13.7 million in LEDA funding to help grow and retain 15 businesses. Those who qualify are expected to show how their company will expand, create jobs and have a local economic impact. 'We are really trying to use the mechanism of these incentives to create generational wealth for our families in Albuquerque,' said Gruner. Vitality Works produces 50,000 bottles of supplements and more a day. Coven believes his company is a way to give back to New Mexico as he employs more than 300 people and he sources some herbs in the state. His company is receiving it's second LEDA funding, which he hopes to use to expand the company even further by adding another 30,000 square feet to his facility. 'Our plans are to keep capturing the growth. We have to keep expanding,' said Coven. State LEDA funds are appropriated by the legislature, while participating cities also have their own LEDA funds, which are controlled by city councils. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
9 hours ago
- Business Wire
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.
Yahoo
9 hours ago
- Yahoo
Is J.B. Hunt Transport Stock Underperforming the S&P 500?
Lowell, Arkansas-based J.B. Hunt Transport Services, Inc. (JBHT) provides surface transportation, delivery, and logistics services in the United States. With a market cap of $13.8 billion, the company operates through five segments: Intermodal (JBI), Dedicated Contract Services (DCS), Integrated Capacity Solutions (ICS), Final Mile Services (FMS), and Truckload (JBT). Companies worth $10 billion or more are typically referred to as "large-cap stocks." JBHT fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the integrated freight & logistics industry. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Despite its strengths, the stock has dipped 30.6% from its 52-week high of $200.40 touched on Nov. 11, 2024. Moreover, over the past three months, JBHT stock has declined 5.5%, underperforming the S&P 500 Index's ($SPX) 5.4% uptick during the same time frame. JBHT stock has declined 18.6% on a YTD basis, underperforming SPX's 1.7% uptick in 2025. Moreover, JBHT has declined 10.7% over the past 52 weeks, underperforming SPX's 9% gains. JBHT stock has been trading below its 200-day moving average since mid-February and mostly above its 50-day moving average since mid-May. On Apr. 15, JBHT stock declined 2% following the release of its Q1 earnings. The trucking and logistics company posted revenue of $2.92 billion in the period, which met Street forecasts. Moreover, its adjusted earnings for the quarter amounted to $1.17, surpassing the consensus estimates by 1.7%. Within the integrated freight & logistics industry, rival Expeditors International of Washington, Inc. (EXPD) has grown 2.1% in 2025 and has declined 9.2% over the past year, slightly outperforming the stock. Among the 24 analysts covering the JBHT stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $151.33 suggests a modest 8.9% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
